Weeks after launching its first open call for diabetes advocates, Dexcom is spotlighting the resulting group of 16 people in ...
DexCom's growth rate has been improving, but that hasn't been enough of a reason for investors to buy up the stock.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is ...
Hosted on MSN
Why DexCom Stock Is Crashing Today
DexCom beat expectations in the third quarter, and it raised its revenue guidance for the full year. Manufacturing issues are putting pressure on margins. For 2026, the company sees growth missing ...
Bullish option flow detected in DexCom (DXCM) with 4,618 calls trading, 1.3x expected, and implied vol increasing almost 3 points to 63.76%. Dec-25 85 calls and 10/24 weekly 73 calls are the most ...
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads. Piper Sandler highlighted that DexCom stock is currently trading at its lowest valuation level in ...
DexCom was hit with a consumer class action on Oct. 22 in California Southern District Court over allegations it made unauthorized design changes to its G6 and G7 continuous glucose monitors without ...
The research note pointed out that DexCom shares have recently declined despite the upcoming 15-day product cycle and revenue growth that should align more closely with the company’s healthy volume ...
SAN DIEGO - Dexcom, Inc. (NASDAQ:DXCM), a glucose biosensing technology company with a market capitalization of $27.69 billion and an "GREAT" financial health rating according to InvestingPro, ...
As of October 30, 2025, the average one-year price target for DexCom is $102.13/share. The forecasts range from a low of $85.07 to a high of $126.00. The average price target represents an increase of ...
San Diego-based Dexcom Inc., is the target of a class action lawsuit in U.S. district court over the company’s G7 continuous glucose monitors, an action which follows a U.S. FDA warning letter by a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback